Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis

January 31, 2014

DUBLIN, January 31, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/xvxqgs/liver_cancer) have announced the
addition of the “Liver Cancer (Hepatocellular Carcinoma): Disease and Pipeline Analysis”
[http://www.researchandmarkets.com/research/xvxqgs/liver_cancer ] report to their

http://photos.prnewswire.com/prnh/20130307/600769 )

This report offers a unique therapeutic assessment and in-depth market and pipeline
analysis, providing a view of the hepatocellular carcinoma (liver cancer) market not
available elsewhere. The purpose of this report is to give an extensive overview of the
current and future liver cancer market, the activities of the key market players and the
issues surrounding drug development.

This report provides the pharmaceutical industry with a therapeutic assessment,
pipeline analysis, and unique insight into the current clinical trial environment for the
hepatocellular carcinoma (HCC) market.

HCC is the fifth most common cancer diagnosed globally in men, is the third most
common cause of cancer death, and because only one systemic therapy is available, remains
a highly underserved disease, explained Andrew Schafer, President of ISR. With high
incidence and morbidity rates and a lack of available effective therapies, significant
commercial opportunity exists for this orphan drug class.

To support this opportunity, ISR’s newest report provides a thorough disease overview,
discusses major and emerging markets, and compiles an analysis of ongoing and recently
completed HCC trials registered on ClinicalTrials.gov to shed light on trial activity
(reported in aggregate and by industry sponsors).

With this report, sponsors can learn how products in the pipeline could compete in
this market, identify strategic development opportunities, plan global clinical trial and
market access strategies, and assess the competition with a full analysis of companies
participating in this market, Schafer explained.

Additionally, ISR’s report provides a thorough analysis of 10 products currently in
early and late phase development that could result in promising new therapies.

Signal transduction pathways involved in tumor cell proliferation, resistance to
apoptosis, stimulation of angiogenesis, invasiveness, and metastasis have been implicated
in HCC and, therefore, are interesting targets for new therapies, Schafer explained.

Key Topics Covered:

        Copyright and Usage Guidelines
        Table of Abbreviations
        Table of Definitions

Chapter 1 Hepatocellular Carcinoma Overview

Chapter 2 Commercial Rationale

Chapter 3 Environmental Analysis

Chapter 4 Clinical Development Pipeline

Chapter 5 Clinical Trial Environment

Chapter 6 Country Profiles

For more information visit


Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net



SOURCE Research and Markets

Source: PR Newswire

comments powered by Disqus